Headlands Technologies LLC Invests $3.96 Million in Zoetis Inc. $ZTS

Headlands Technologies LLC bought a new stake in Zoetis Inc. (NYSE:ZTS) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 55,106 shares of the company’s stock, valued at approximately $3,960,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Prosperity Bancshares Inc acquired a new stake in Zoetis in the 4th quarter valued at about $25,000. Cassaday & Co Wealth Management LLC acquired a new position in shares of Zoetis during the first quarter worth about $28,000. Elyxium Wealth LLC purchased a new stake in shares of Zoetis during the fourth quarter worth approximately $32,000. Root Financial Partners LLC increased its stake in shares of Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after buying an additional 103 shares during the period. Finally, Wellington Grp LLC raised its holdings in Zoetis by 6,675.0% in the first quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after acquiring an additional 267 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of Zoetis stock opened at $77.45 on Monday. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. Zoetis Inc. has a 52 week low of $71.00 and a 52 week high of $156.49. The firm’s 50 day moving average is $75.57 and its two-hundred day moving average is $95.40. The firm has a market capitalization of $32.00 billion, a P/E ratio of 12.76, a P/E/G ratio of 1.80 and a beta of 0.73.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company’s revenue was down .2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Research analysts forecast that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Argus reiterated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Barclays dropped their price objective on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 1st. JPMorgan Chase & Co. decreased their price objective on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. Piper Sandler lowered their target price on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. Finally, HSBC dropped their target price on Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a report on Monday, July 6th. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Zoetis presently has a consensus rating of “Hold” and an average target price of $107.43.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.